Pay in 4 interest-free payments of $6.74 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
When symptoms return early A subset of people on standard maintenance notice their symptoms come back well before the next scheduled dose
The excellent safety profile observed in obese participants suggests that AOD-9604 is well-tolerated even in individuals with obesity-related comorbidities
AOD-9604 demonstrates selectivity for adipose tissue without promoting muscle protein breakdown
They are not FDA-approved to diagnose, treat, cure, or prevent any disease
When Direct Medical Supervision Is Required While many can manage their injections, some need direct medical supervision
THE PRODUCTS DESCRIBED HEREIN ARE FOR RESEARCH USE ONLY
US$ 24.80
US$ 22.73
US$ 29.35
US$ 26.77
US$ 20.28
